2024 PDA


VIRUS CONFERENCE



pda.org/EU/2024Virus

26-27 JUNE 2024 AMSTERDAM, THE NETHERLANDS

EXHIBITION: 26-27 JUNE 2024 WORKSHOP: 28 JUNE 2024



WELCOME FROM THE CO-CHAIRS

Dear Colleague,

We would like to invite you to submit a paper or poster abstract for presentation for the **2024 PDA Virus Conference** to be held on **26-27 June 2024** in Amsterdam, The Netherlands.

Abstracts must be non-commercial in nature, describing new developments or work that significantly contributes to the body of knowledge relating to virus safety and all related aspects as stated below.

The Scientific Program Planning Committee will review all proposals carefully and consider podium and poster contributions.

We look forward to receiving your topic proposal!

Sincerely,

The Co-Chairs



Andy Bailey, ViruSure



Sean O'Donnell, *Eli Lilly and Company*

CALL FOR ABSTRACTS

TOPICS AREAS OF INTEREST WILL INCLUDE BUT .



1. REGULATORY UPDATES

- International Perspectives
- · Updates on EP/USP/JP Chapters
- · Update on ICH Q5A R2 Guideline
- Regulatory Requirements for Virus Safety Testing and Virus Clearance Studies
- Impact of Regulatory Requirements on Business



2. CURRENT AND EMERGING VIRUSES

- · Hepatitis E Virus
- · Paroviruses
- COVID-19
- · Zika
- West Nile
- · Swine flu
- Measles
- MERSEbola
- Monkey Pox
- · Circovirus
- Zoonoses



3. VIRUS SAFETY OF STARTING AND RAW MATERIALS

- · Risk Assessment
- · Virus Mock Particles
- Case Studies for Media Treatment
- · New Threats to Human Plasma
- · Cell Substrate Safety
- · Raw Materials
- · Material Selection
- · Supplier Audits and Qualification
- · Cell-Sorting Antibodies
- · Serum and Trypsin
- · Antibody Drug Conjugates
- Adventitious Viruses/Adventitious Agents
- Prevention of Contamination
- · Utilization of Prior Knowledge
- Substances of Human Origin and Animal-Derived



4. VIRUS DETECTION AND IDENTIFICATION

- · Virus Detection Methods
- Virus-Like Particles
- Developments of New Detection Methods
- Next Generation Sequencing/ High Throughput Sequencing
- Technical Operation of Next Generation Sequencing Platforms, e.g., Automation, Time to Result
- Targeted vs. Agnostic Next Generation Sequencing
- Next Generation Sequencing Bioinformatics
- Product-Enhanced Reverse Transcriptase Assay
- · Nucleic Acid-Based Methods
- Digital-Droplet Polymerase Chain Reaction
- Model Organisms, Equipment, and Conditions
- Replacement of Animal/In-Vivo Tests and 3R Initiative
- Cell-Based Assays/HEV Infectivity Assay
- Emerging and Hard-to-Detect Viruses
- Transmission Electron Microscopy
- Artificial Intelligence

CASE STUDIES AND CURRENT CHALLENGES ARE OF SPECIAL INTEREST.

SCIENTIFIC PROGRAM PLANNING COMMITTEE

Andy Bailey, ViruSure

Sean O'Donnell, Eli Lilly and Company

Alison Armstrong, Merck KGaA

Chakameh Azimpour, Amgen

Johannes Bluemel, Paul-Ehrlich-Institut

David Cetlin, Cygnus

Qi Chen, Genentech/Roche

Tomoko Hongo, Asahi Kasei

Arifa Khan, U.S. FDA

Thomas R. Kreil, Takeda

Remo Leisi, CSL Behring

Sebastian Teitz, Biopharma Excellence

Josh Eaton, PDA

Falk Klar, PDA Europe

Stefanie Nebelin, Senior Manager Programs & Events, PDA Europe





AMSTERDAM MARRIOTT HOTEL

Stadhouderskade 12, 1054 ES Amsterdam, The Netherlands Tel: +31 20-6075555

E-Mail: Amsterdam@Marriott.com | https://bit.ly/461euWo

ARE NOT LIMITED TO THE FOLLOWING



5. VIRAL SAFETY OF ATMPS

- · Human Platelet Lysates and Sera
- Viral Vectors
- · Virus Safety of Cell Lines
- Helper Virus Production
- · Viral Clearance
- Viral Vector Purification Process
- Xenogeneic Cells Used as Feeder Layer or Therapeutic Substance
- Case Studies for Cell and Gene-Based Medicinal Products
- Extracellular Vesicles
- Virus Reduction Studies
- Transplantation (e.g., Xenotransplantation)
- Medical Devices



6. VIRAL CONTAMINATION AND **RISK MITIGATION IN THE MANUFACTURING PROCESS**

- · Risk Assessment
- Cell Culture Media Treatment
- Viral Clearance
- Virus Filtration/Nano Filtration
- · Standards for Vectors



7. TSE CONTAMINATION AND RISK MITIGATION

- Raw Materials
- **Blood Products**
- Cell-Based Products
- Cell Substrates
- Infectability of Cell Substrates
- New Concepts for Testing and Identification
- Inactivation Strategies and Equipment



ASPECTS OF FOOD AND WATERBORNE VIRUS SAFETY

- Norovirus-Related Diseases
- Rotavirus-Related Diseases
- Identification of Viruses in Food
- Transmission Pathways
- Risk Assessments
- **Cultured Meat Products**



9. VIRUS SAFETY IN **MANUFACTURING**

- · Biopharmaceuticals
- Plasma-Derived Medicinal Products
- Viral Vaccines
- Irradiation (Gamma, Electrons, X-Rays)
- Inactivation
- Removal
- Filtration
- Prion-Specific Filtration Methods
- Chromatography
- Precipitation
- Case Studies
- Risk Assessments
- Continuous Manufacturing
- · Platform Approach
- Technical Developments/ Innovation
- · Analytical Methods
- · Integrated Recycling Process
- · Reduction of Wastewater
- Waste Prevention and Handling
- **Environmental Protection**
- · Recycling Economy



10. VIRUS REDUCTION STUD-

- **IES** Design of Studies
- DoE Studies
- Case Studies on Platform Validation
- Mechanism of Action of Virus Removal/Inactivation
- Robustness of Specific Unit Operations
- Identification of Critical Process **Parameters**
- · Spike Preparations
- Scalability of Study Design and Study Results
- Sanitization of Chromatographic Equipment
- Columns Including Virus-Carry-Over Studies
- · Impact of Virus Spike Quality
- **Developments in Laboratory** Automation

DEADLINE: 30 NOVEMBER 2023

All submitted abstracts will be reviewed by the Scientific Program Planning Committee for acceptance. PDA Europe will provide a complimentary registration per on-site podium presentation.

Additional on-site presenters are required to pay the conference registration fee.

Abstracts not selected for a podium presentation may be invited to join as a scientific poster contribution. On-site poster presenters are required to pay the conference registration fee and an additional printing fee will apply.

THE ONLINE PROCESS ASKS YOU TO PROVIDE THE FOLLOWING INFORMATION:

- PRESENTATION TITLE
- PRESENTER'S NAME AND CONTACT DETAILS
- PRESENTER'S BIOGRAPHY (APPROX. 100 WORDS)
- ADDITIONAL SPEAKERS (IF APPLICABLE)
- KEY OBJECTIVES OF TOPIC
- 2-3 PARAGRAPH ABSTRACT, SUMMARIZING THE TOPIC (MAX 300 WORDS)


Please click or scan the QR Code to submit your abstract.



bit.ly/32sDvHz

If you have any further questions, please do not hesitate to contact programs-europe@pda.org

TO EXHIBIT: PDA is seeking vendors who provide products/services in support of this conference. Space on-site is limited and is on a first-come, first-serve basis. To reserve your space, please contact Christopher Haertig at **expo-europe@pda.org.**



ALL POSTERS WILL BE PRINTED BY PDA AND DISPLAYED AS PART OF THE EXHIBITION.

Please send your file and poster title to Christopher Haertig expo-europe@pda.org.

JOIN OUR GUIDED POSTER WALK IN OUR EXHIBITION HALL AND GAIN MORE VISIBILITY

YOU WILL HAVE THE CHANCE TO ENGAGE WITH OUR POSTER AUDIENCE!

CONFERENCES AND EVENTS



FOR FURTHER INFORMATION FOLLOW US ONLINE

www.pda.org

2024	13. Oct 2023	
09-10 APR 2024	2024 PDA Visual Inspection Forum	Munich, Germany
23-24 APR 2024	2024 PDA Parenteral Packaging Conference	Copenhagen, Denmark
15-16 MAY 2024	2024 PDA Good Aseptic Manufacturing Conference	Stuttgart, Germany
04-05 JUN 2024	2024 PDA Good Digitalization in Pharma Conference	ТВА
04-05 JUN 2024	2024 PDA Medical Devices and Connected Health Conference	ТВА
06 JUN 2024	2024 PDA Artificial Intelligence in Pharma Workshop	ТВА
06 JUN 2024	2024 PDA The Future of Drug Delivery Workshop	ТВА
24-25 JUN 2024	2024 PDA Advanced Therapy Medicinal Products Conference	Amsterdam, The Netherlan
26-27 JUN 2024	2024 PDA Virus Conference	Amsterdam, The Netherlan
28 JUN 2024	2024 PDA Next-Generation Sequencing Workshop	Amsterdam, The Netherlan
24-25 SEP 2024	2024 PDA BioManufacturing Conference	Gothenburg, Sweden
26 SEP 2024	2024 PDA Sustainability in Pharma Workshop	Gothenburg, Sweden